Shanghai Pharmaceuticals Holding Co., Ltd. (SH PHARMA) disclosed its Monthly Return for the period ended 31 May 2026, confirming that no movements occurred in either its authorised or issued share capital during the month.

The group’s authorised share capital remains at 3.71 billion shares, split between 919.07 million H-shares and 2.79 billion A-shares, each with a par value of RMB 1.00.

Issued shares also stayed unchanged at 3.71 billion—comprising 919.07 million H-shares listed in Hong Kong and 2.79 billion A-shares listed in Shanghai. The company held no treasury shares as of month-end.

SH PHARMA confirmed that its H-share public float continues to satisfy the Hong Kong Stock Exchange’s minimum requirement—5 % of the total issued H-shares—demonstrating full regulatory compliance.

No share options, warrants, convertibles, or other equity instruments were issued, exercised, or cancelled during the reporting period, and no other equity movements were recorded.

The filing was signed by Joint Company Secretary Zhong Tao and submitted to Hong Kong Exchanges and Clearing Limited on 1 June 2026.